RecruitingNCT03296826
Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2
Sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Enrollment
600 participants
Start Date
Nov 8, 2017
Study Type
OBSERVATIONAL
Conditions
Summary
To determine the incidence and risk factors in the development of ovarian, fallopian tube, and peritoneal cancers in Japanese women carrying Breast Cancer Susceptibility Gene (BRCA)1/2 variants.
Eligibility
Sex: FEMALEMin Age: 20 Years
Inclusion Criteria4
- Women carrying BRCA1/2 variants (those with either BRCA1 or BRCA2 variants, or those carrying both variants) and women carrying a variant of uncertain significance (VUS).
- Women who have received sufficient genetic counseling at any medical institution, prior to enrollment to the study.
- Women who provide consent should be 20 years of age or older.
- Women who provide written consent.
Exclusion Criteria3
- Women without ovarian or fallopian tube cancer at the time of informed consent.
- Women previously diagnosed with ovarian, fallopian tube, or peritoneal cancer, and not excluding those with a personal history of breast cancer development.
- Other individuals considered inappropriate for involvement in this study by the investigator.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03296826
Related Trials
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT0699589836 locations
National Cancer Institute "Cancer Moonshot Biobank"
NCT04314401152 locations
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
NCT074809541 location
Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
NCT072821581 location
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
NCT063214842 locations